Kaiqiang Li, Jing Jin, Yimin Yang, Xuling Luo, Yaling Wang, Aibo Xu, Ke Hao, Zhen Wang
{"title":"Application of Nanoparticles for Immunotherapy of Allergic Rhinitis.","authors":"Kaiqiang Li, Jing Jin, Yimin Yang, Xuling Luo, Yaling Wang, Aibo Xu, Ke Hao, Zhen Wang","doi":"10.2147/IJN.S484327","DOIUrl":null,"url":null,"abstract":"<p><p>Allergen Immunotherapy (AIT) is the only etiological therapeutic method available for allergic rhinitis (AR). Currently, several options for AIT in the market, such as subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), have different routes of administration. These traditional methods have achieved encouraging outcomes in clinic. However, the side effects associated with these methods have raised the need for innovative approaches for AIT that improve safety, shorten the course of treatment and increase local drug concentration. Nanoparticles (NPs) are particles ranging in size from 1 to 100 nm, which have been hired as potential adjuvants for AIT. NPs can be employed as agents for modulating immune responses in AR or/and carriers for loading proteins, peptides or DNA molecules. This review focuses on different kinds of nanoparticle delivery systems, including chitosan nanoparticles, exosomes, metal nanoparticles, and viral nanoparticles. We summarized the advantages and limitations of NPs for the treatment of allergic rhinitis. Overall, NPs are expected to be a therapeutic option for AR, which requires more in-depth studies and long-term therapeutic validation.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"19 ","pages":"12015-12037"},"PeriodicalIF":6.6000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584337/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nanomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJN.S484327","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Allergen Immunotherapy (AIT) is the only etiological therapeutic method available for allergic rhinitis (AR). Currently, several options for AIT in the market, such as subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), have different routes of administration. These traditional methods have achieved encouraging outcomes in clinic. However, the side effects associated with these methods have raised the need for innovative approaches for AIT that improve safety, shorten the course of treatment and increase local drug concentration. Nanoparticles (NPs) are particles ranging in size from 1 to 100 nm, which have been hired as potential adjuvants for AIT. NPs can be employed as agents for modulating immune responses in AR or/and carriers for loading proteins, peptides or DNA molecules. This review focuses on different kinds of nanoparticle delivery systems, including chitosan nanoparticles, exosomes, metal nanoparticles, and viral nanoparticles. We summarized the advantages and limitations of NPs for the treatment of allergic rhinitis. Overall, NPs are expected to be a therapeutic option for AR, which requires more in-depth studies and long-term therapeutic validation.
过敏原免疫疗法(AIT)是目前治疗过敏性鼻炎(AR)的唯一病因治疗方法。目前,市场上有多种过敏原免疫疗法可供选择,如皮下免疫疗法(SCIT)和舌下免疫疗法(SLIT),它们的给药途径各不相同。这些传统方法在临床上取得了令人鼓舞的成果。然而,由于这些方法存在副作用,因此需要创新的 AIT 方法来提高安全性、缩短疗程并增加局部药物浓度。纳米粒子(NPs)是一种大小从 1 纳米到 100 纳米不等的颗粒,已被用作 AIT 的潜在佐剂。NPs 可用作调节 AR 免疫反应的制剂或/和载入蛋白质、肽或 DNA 分子的载体。本综述重点讨论了不同种类的纳米颗粒递送系统,包括壳聚糖纳米颗粒、外泌体、金属纳米颗粒和病毒纳米颗粒。我们总结了纳米粒子在治疗过敏性鼻炎方面的优势和局限性。总之,NPs有望成为AR的一种治疗选择,这需要更深入的研究和长期的治疗验证。
期刊介绍:
The International Journal of Nanomedicine is a globally recognized journal that focuses on the applications of nanotechnology in the biomedical field. It is a peer-reviewed and open-access publication that covers diverse aspects of this rapidly evolving research area.
With its strong emphasis on the clinical potential of nanoparticles in disease diagnostics, prevention, and treatment, the journal aims to showcase cutting-edge research and development in the field.
Starting from now, the International Journal of Nanomedicine will not accept meta-analyses for publication.